The inflammatory responses in Alzheimer's disease and prion diseases are dominated by microglia activation. Three different phenotypes of microglial activation, namely classical activation, alternative activation, and acquired deactivation, have been described. In this study, we investigated the effect of amyloidogenic fragments of amyloid b and prion proteins (Ab 1-42 and PrP 106-126 ) on various forms of microglial activation. We first examined the effect of Ab 1-42 and PrP 106-126 stimulation on the mRNA expression levels of several markers of microglial activation, as well as the effect of cytochalasin D, a phagocytosis inhibitor, on microglial activation in Ab 1-42 -and PrP 106-126 -stimulated BV2 microglia. Results showed that Ab 1-42 and PrP 106-126 induced the classical activation of BV2 microglia, decreased the expression level of alternative expression markers, and had no effect on the expression of acquired deactivation markers. Cytochalasin D treatment significantly reduced Ab 1-42 -and PrP 106-126 -induced up-regulation of proinflammatory factors, but did not change the expression profile of the markers of alternative activation or acquired deactivation in BV2 cells which were exposed to Ab 1-42 and PrP 106-126 . Our results suggested that microglia interact with amyloidogenic peptides in the extracellular milieu-stimulated microglial classical activation and reduce its alternative activation, and that the uptake of amyloidogenic peptides from the extracellular milieu amplifies the classical microglial activation.
Introduction
The abnormal assembly and deposition of amyloid fibrils in brain characterizes a diverse group of neurodegenerative disorders including Alzheimer's disease (AD), Parkinson's disease, Huntington's disease, and prion diseases [1] and many of them involving the degeneration of neurons and microglial activation [2] . Prion and AD are neurodegenerative disorders characterized neuropathologically by the presence of extracellular amyloid deposits, extensive neuronal loss, and gliosis. In AD, the amyloid deposits are composed of amyloid-beta (Ab) peptides, which result from the abnormal proteolytic cleavage of the amyloid precursor protein [3] , whereas, in prion diseases, the amyloid deposits are constituted mainly by the scrapie isoform of the prion protein (PrP Sc ), a conformational variant of the cellular prion protein (PrP C ) [4] . PrP 106 -126 is a peptide fragment that mimics PrP Sc toxicity and forms fibrils in vitro and is commonly used as a model for investigating prion disease [5] [6] [7] [8] .
Microglia are the principal immune effector cells in the central nervous system, and play an important role in receiving and propagating inflammatory signals in response to the activation of peripheral immune system. In the absence of inflammatory stimuli, microglia are quiescent even though they are actively involved in immune surveillance [9, 10] . In response to inflammatory triggers, microglia are activated and display macrophage-like capabilities including phagocytosis, antigen presentation, and inflammatory cytokines production [11, 12] ; this proinflammatory state is known as classical activation and the main identifying features of this state include the over-expression of tumor necrosis factoralpha (TNF-a) and nitric oxide synthase 2 (NOS2).
Microglia have been demonstrated to show an antiinflammatory alternative activation phenotype when stimulated with IL-4 or IL-13 [13] . These alternatively activated cells produce several components associated with tissue repair and reconstruction after injury [14] [15] [16] [17] . The overexpression of arginase 1 (Arg1) and mannose receptor 1 (Mrc1) characterizes this state of activation.
Recently, a third subtype of microglial activation, termed acquired deactivation, has been identified [13] . This phenotype
is induced by IL-10 and incorporates a mixed-phenotype population that exhibits immunosuppression and is associated with the uptake of apoptotic cells. This type of activation is characterized by the up-regulation of suppressor of cytokine signaling 3 (SOCS3) and interleukin 4 receptor a (IL-4Ra).
In this study, we investigated the effect of the exposure to amyloidogenic fragments Ab 1 -42 and PrP 106 -126 on microglial activation. Results showed that the exposure led to classical activation, reduced alternative activation and had no effect on acquired deactivation. Cytochalasin D, a phagocytosis inhibitor, reduced classical activation of BV2, but had no effect on the other two types of activation.
Materials and methods
Ab 1 -42 and PrP 106 -126 treatment Ab 1 -42 and reverse control Rev 42 -1 peptides were purchased from UNIV-bio (Beijing, China). For fibril formation, Ab peptides were resuspended in sterile phosphate buffer solution (PBS) (final concentration, 1 mM) and incubated at 378C for 1 week. Experiments were conducted with final peptide concentrations of 5 mM [18] . PrP 106 -126 (KTNMKHMAGAAA AGAVVGGLG) and scramble PrP (Scr, AVGMHAGKG LANTAKAGAMVG) were purchased from Sangon BioTech (Shanghai, China) and dissolved in sterile PBS to a concentration of 1 mM and left to aggregate at 378C for 12 h. The experiments were conducted with final peptide concentrations of 50 mM [18, 19] .
Cell culture and treatment conditions BV2 microglial cells, a murine microglia cell line, were obtained from Union Medical University (Beijing, China). Cells were cultured in DMEM and F12 medium (Hyclone, Logan, USA) supplemented with 10% heat-inactivated FBS (Gibco, Grand Island, USA), 100 mg/ml streptomycin, 100 U/ml penicillin (Gibco), and 2 mM glutamine at 378C with 5% CO 2 . For each experiment, 2 Â 10 5 cells were plated into 12-well plates, cultured for 12 h, and then stimulated with Ab 1 -42 (5 mM) or PrP 106 -126 (50 mM) for 1, 12, 24, 36, 48, and 60 h, respectively, at 378C in a 5% CO 2 humidified atmosphere. For cytochalasin D treatment, BV2 cells were co-treated with PrP 106 -126 and 2 mM cytochalasin D (Fermentek, Israel) or Ab 1 -42 and 2 mM cytochalasin D for 12, 24, and 36 h, respectively. Then cells were collected for RNA extraction. All experiments were performed for three times.
Enzyme-linked immunosorbent assay (ELISA) for TNF-a and iNOS secretion Cell culture supernatants were assayed for TNF-a and iNOS with ELISA kit from Boster Biotech (Wuhan, China) according to manufacturer's instructions.
Thioflavine-T fluoreometric assay
The fibril formation of Ab 1 -42 and PrP 106 -126 was measured by using a thioflavine-T (ThT) fluorometric assay according to published reports [20] .
RNA isolation and complementary DNA synthesis Total RNA of BV2 cells was extracted using SV Total RNA Isolation System (Promega, Madison, USA), and reverse transcribed into cDNA by using cDNA synthesis kit (Fermentas, Glen Burnie, USA) and oligo(dT) 18 primers. In accordance with manufacturer's instructions, a final volume of 20 ml was used and incubated for 60 min at 428C, containing RNA template (1 mg), dNTPs (0.5 mM), oligo(dT) primers (1 mM), RT buffer, and nuclease-free water and enzyme was inactivated at 708C for 5 min.
Quantitative polymerase chain reaction Quantitative polymerase chain reaction (qPCR) was performed by using SYBR Green I Master Mix (Bio-Rad, Hercules, USA) and a thermal cycler (DNA Engine Opticon TM 2 system; MJ Research, Waltham, USA) with primers shown in Table 1 . The qPCR amplification reaction was performed in a final volume of 20 ml, containing 10 ml Master Mix, 0.5 ml of each primer (10 mM), 30 ng of cDNA and water. The amplification procedure was as follows: denaturation at 958C for 2 min; 40 PCR cycles of 958C for 5 s, 558C for 20 s, 728C for 30 s; 1 cycle at 848C for 1; 10 s at 708C and slow heating at a rate of 0.2 per second up to 1008C with continuous fluorescence measurement. Quantification was performed by using comparative C T method (2 2DDCT ) [21] . All samples were analyzed in triplicate. 
Discussion
To better understand the nature of interactions between microglia and amyloidogenic fragments during Alzheimer's and prion disease, we investigated the effect of exposure to amyloidogenic fragments on the activation state of microglia. BV2 microglia were therefore exposed to synthetic fragments Ab 1 -42 or PrP 106 -126 , and the expression level of specific markers of different microglial activation phenotypes was were measured by quantitative PCR and were expressed as fold changes relative to the mRNA level in control cells which were exposed to PBS only. The secretion of TNF-a and NO was tested by using ELISA (B), and the presence of amyloid aggregates of Ab 1 -42 using thioflavine-T (ThT) fluorometric assay (E). Data were expressed as mean + SD of triplicate experiments. *P , 0.05.
Inhibition of phagocytosis reduced the classical activation of BV2
determined at various post-exposure time points. Results showed that the expression profile of all examined genes upon exposure to either Ab 1 -42 or PrP 106 -126 was basically identical, which supported the close similarity in microglia-associated pathogenic processes during Alzheimer's and prion diseases.
Ab 1 -42 or PrP 106 -126 induces the proinflammatory classical activation of microglia, which is consistent with the well-established fact of microglia-associated proinflammatory process during Alzheimer and prion diseases [22, 23] .
The analysis of the effect of amyloidogenic fragments treatment on genes associated with alternative activation of microglia revealed that Ab 1 -42 or PrP 106 -126 treatment reduced the expression level of Arg1 and Mrc1 below control level. These results suggested that the exposure to amyloidogenic peptides Inhibition of phagocytosis reduced the classical activation of BV2 might increase the threshold for microglial alternative activation. However, these findings were not consistent with those from previous reports which showed that neurodegenerative diseases, including AD, are characterized by co-expression of alternative activation and classical activation of the microglia in the brain of affected animals or patients [24] . In light of the findings we reported here, a possible explanation of the alternative microglial activation observed in previous reports was that other cerebral cells such as neuron and astrocytes were stimulated to release anti-inflammatory factors such as IL-4, which might be an indirect result of the amyloidogenic peptides-induced proinflammatory process. These factors in turn stimulated alternative activation of microglia and permitted the establishment of a balance between the opposite poles of proinflammation and increased self-toxicity and antiinflammation and longer tissue survival in activated microglia in neurodegenerative diseases.
When compared with control, exposure to Ab 1 -42 or PrP 106 -126 had no significant effect on the expression level of SOCS3 and IL-4Ra, two genes associated with the third phenotype of microglial activation, also known as acquired deactivation, suggesting that this activation phenotype did not play a relevant role in the pathogenesis of Alzheimer's and prion diseases.
Cytochalasin D treatment significantly reduced Ab 1 -42 -and PrP 106 -126 -induced up-regulation of proinflammatory factors, suggesting that the most important part of the stimulatory effect of amyloidogenic peptides took place only after their uptake inside BV2 cells, and that this stimulatory effect started as early as microglia interact with amyloidogenic peptides in extracellular milieu. This result also highlighted the importance of phagocytosis in the pathogenesis of amyloidogenic neurodegenerative diseases and confirms previous reports of the involvement of phagocytosis in the establishement of the neuro-inflammatory process associated with AD [25] .
Taken together, our results suggest that the interactions of microglia with amyloidogenic peptides in the extracellular milieu stimulate microglial classical activation and reduce its alternative activation, and that the uptake of amyloidogenic peptides from the extracellular milieu amplifies classical microglial activation.
